Roche Holding AG
Gesloten
SectorGezondheidszorg
373.2 0.92
Overzicht
Wijziging aandelenprijs
24u
Min
373.2
Max
374.6
Inkomsten | 1.4B 6.9B |
|---|---|
Verkoop | -208M 30B |
K/W Sectorgemiddelde | 23.632 68.51 |
Dividendrendement | 2.72 |
Winstmarge | 22.629 |
Werknemers | 103,249 |
EBITDA | -2.2B 9.4B |
Dividendrendement Sectorgemiddelde | 2.72% 2.29% |
|---|
Marktkapitalisatie | 22B 288B |
|---|---|
Vorige openingsprijs | 372.28 |
Vorige sluitingsprijs | 373.2 |
Roche Holding AG Grafiek
Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.
Gerelateerd nieuws
Peer Vergelijking
Prijswijziging
Roche Holding AG Prognose
Financieel
Verkoop- en administratiekosten
Bedrijfskosten
Winst voor belastingen
Verkoop
Kosten van verkopen
Brutowinst op verkopen
Rente-uitgaven op schulden
EBITDA
Operationele winst
$
Over Roche Holding AG
Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and Oceania. The company offers pharmaceutical products in the therapeutic areas of anemia, blood and solid tumors, dermatology, hemophilia, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation. It is also developing products for various therapeutic areas. In addition, it offers in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavirus, and other diseases; diagnostic instruments; and digital health solutions. It has strategic discovery collaboration with Flare Therapeutics Inc. proteomic and mass spectrometry platform and expertise to discover novel small molecules aimed at transcription factor targets in oncology. Roche Holding AG was founded in 1896 and is based in Basel, Switzerland.